Abstract 522P
Background
Adding an immune checkpoint inhibitor (ICI) to chemotherapy has demonstrated efficacy in treating extensive-stage small cell lung cancer (ES-SCLC). However, patients with idiopathic interstitial pneumonia (IIP) have a higher risk of developing pneumonitis associated with anticancer therapy. We conducted a multicenter, single-arm trial to evaluate the safety and efficacy of durvalumab plus etoposide and carboplatin for patients with ES-SCLC and mild IIP.
Methods
Eligible patients were those who had not been previously treated with ES-SCLC and mild IIPs. Mild IIP was defined as predicted vital capacity (VC) ≥80%; no collagen vascular disease-associated antibodies; and chest high-resolution computed tomography image revealed a probable UIP, indeterminate for UIP, or alternative diagnosis pattern. The primary endpoint was severe-pneumonitis-free (SPF) rate, which was defined as the rate of patients who did not develop Grade 3 or higher pneumonitis. The study treatment was feasible if the SPF rate was 90% or more, and grade 5 pneumonitis was found within one patient.
Results
In total, 22 cases were enrolled, and 21 were included in the analysis. The median age was 74 years (range, 65–82). Most patients had stage Ⅳ disease (90%) and Eastern Cooperative Oncology Group Performance Status of 1 (67%). The median %VC was 96.1% (range 81.3–117.8). Thirteen patients displayed a probable UIP pattern, while 8 were indeterminate for UIP pattern. The SPF rate was 95.2% (20/21). The incidence of pneumonitis was 9.5% (2/21) for all grades. One patient had grade 5 pneumonitis.
Conclusions
Durvalumab plus etoposide and carboplatin can be a feasible treatment option for patients with ES-SCLC and mild IIPs.
Clinical trial identification
The Japan Registry of Clinical Trials: jRCTs051200109.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca PLC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract